Home › Research › Treatments
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial
Sato Y, Kanoko T, Satoh K, Iwamoto J.. Archives of internal medicine, 2005-08-01
This paper has been retracted. The record we hold marks it as a retracted publication. Check the original source below for the retraction notice before relying on anything it reports.
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that deficiency of 25-hydroxyvitamin D and compensatory hyperparathyroidism cause reduced bone mineral density in female patients with AD. We address the possibility that treatment with risedronate sodium and ergocalciferol plus calcium supplementation may reduce the incidence of nonvertebral fractures in elderly women with AD. Methods A total of 500 elderly women with AD were randomly assigned to daily treatment with 2.5 mg of risedronate sodium or a placebo, combined with 1000 IU of ergocalciferol and 1200 mg of elementary calcium, and followed up for 18 months. Results At baseline, patients of both groups showed 25-hydroxyvitamin D deficiency with compensatory hyperparathyroidism. During the study period, bone mineral density in the risedronate group increased by 4.1% and decreased by 0.9% in the control group. Vertebral fractures occurred in 29 patients (24 hip fractures) in the control group and 8 patients (5 hip fractures) in the risedronate group. The relative risk in the risedronate group compared with the control group was 0.28 (95% confidence interval, 0.13-0.59). Conclusions Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. Treatment with risedronate and ergocalciferol may be safe and effective in reducing the risk of a fracture in elderly patients with AD.
What this study adds
Evidence grade: Low
This is a trial of 29 participants. In this 18-month trial of 500 elderly women with Alzheimer's disease, risedronate plus vitamin D and calcium reduced the risk of fractures, including hip fractures. Reported effect size: increased by 4.1%; decreased by 0.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005). The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Archives of internal medicine. https://doi.org/10.1001/archinte.165.15.1737
Vancouver
Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Archives of internal medicine. 2005. doi:10.1001/archinte.165.15.1737. PMID: 16087821.
BibTeX
@article{sato2005-16087821,
author = {Sato, Y. and Kanoko, T. and Satoh, K. and Iwamoto, J.},
title = {{The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial}},
journal = {Archives of internal medicine},
year = {2005},
doi = {10.1001/archinte.165.15.1737},
pmid = {16087821},
url = {https://doi.org/10.1001/archinte.165.15.1737}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results At baseline, patients of both groups showed 25-hydroxyvitamin D deficiency with compensatory hyperparathyroidism.
- The relative risk in the risedronate group compared with the control group was 0.28 (95% confidence interval, 0.13-0.59).
- Conclusions Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture.
Why it matters
In this 18-month trial of 500 elderly women with Alzheimer's disease, risedronate plus vitamin D and calcium reduced the risk of fractures, including hip fractures. This treatment addresses fracture prevention in these patients and does not treat, cure, or prevent Alzheimer's disease itself.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants29
- Effect sizeincreased by 4.1%; decreased by 0.9%
- Evidence strengthLow
How this study scored 16/100
Retracted — do not rely on it. It scored 36 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Archives of internal medicine) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 0 / 10 | Retracted — do not rely on it. PubMed indexes it as a Retracted Publication. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 1 / 4 | 29 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 4 / 7 | Cited 70 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 3 / 6 | Cited 6.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jun Iwamoto: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Mitate Hospital: institution h-index 41 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16087821) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 36 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.